Market Opportunities
Infectious Disease -
The global antibiotic market was valued at $28B in 2002, the third largest sector in the global pharmaceutical market. Market dynamics in the antibiotic sector reflect its mature nature - there are large numbers of competing products and varied treatment guidelines.
There exists a significant need in the community and hospital settings to develop novel non-antibiotic preventative and therapeutic agents for infectious disease. Key drivers of demand in these markets include:
- Increased incidence of resistant pathogens such as MRSA, VRE, and FQRP;
- An ever increasing elderly population;
- Increased number of immune-compromised patients, such as cancer patients, patients with acquired immune deficiency syndrome (AIDS) and patients receiving immunosuppressive treatment; and
- The need for rapid preventative measures in emergency situations following major disasters (earthquakes, flooding, etc.) or bioterrorist attack.
Inimex medicines have a number of key advantages that address these market drivers for infectious disease:
Inimex Product Advantages:
- Avoidance of drug resistance
- Fast-acting
- Broad-spectrum activity
- Suppression of inflammation
- Independence from T & B cells
Inimex compounds rapidly trigger host innate immunity, even in animals that are genetically or chemically immune stressed. Triggering the innate system results in naturally broad spectrum defence against pathogens; in mouse models Inimex compounds have been shown to have activity against Gram positive, Gram negative and antibiotic resistant bacterial infections. Given that Inimex compounds act on the host species, it is not expected that bacteria will become resistant to their mode of action.
INFLAMMATORY DISEASE
In addition to fighting infection, Inimex medicines have potential application in inflammatory disease. Inimex compounds suppress inflammation in a variety of animal models and have been shown to reduce the production of the proinflammatory cytokine TNF-a. This suggests that Inimex compounds would represent a competing approach to anti-TNF-a therapies currently on the market, with combined worldwide annual sales >$4.8B for the three agents.
Inimex compounds would have a lower cost of goods than currently marketed anti-TNF-a therapies and, given their inherent anti-infective properties, Inimex compounds would not suffer from the enhanced susceptibility to infection associated with current therapies.
ADDITIONAL OPPORTUNITIES
The market opportunities will be sizeable for an orally available second generation product. For example, the annual market for community pneumonia products in the US is estimated at $4B annually and the global antiviral market at $20B. First and second generation Inimex products also have application and significant potential for a number of other infectious disease franchises, including emergency response / biodefence, animal healthcare and third world diseases.
For more information
> Inimex Product Profile
193KB pdf format
